Immunohistochemical evaluation of IGF1R phosphorylation and PTPN9 expression in baseline tumor biopsies may serve as a valuable tool to stratify patients who are most likely to benefit from IGF1R-directed combination therapies, thereby facilitating biomarker-driven clinical trial designs. Here, IGF1R is linked to neoplasm.